EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance

Tatiana Kekeeva iD, Irina Dudina, Yulia Andreeva, Alexander Tanas iD, Alexey Kalinkin iD, Victoria Musatova, Natalia Chernorubashkina iD, Svetlana Khokhlova iD, Tatiana Tikhomirova, Mikhail Volkonsky, Sergey Kutsev, Dmitry Zaletaev iD und 1 weitere

International Journal of Molecular Sciences · 18.12.2024 · 25 (24) · 13549

DOI: 10.3390/ijms252413549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.12.2024. Verfasst von Tatiana Kekeeva und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia. Hauptthemen laut MEDLINE: Ovarian Neoplasms, BRCA2 Protein, DNA Methylation, BRCA1 Protein. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination repair deficiency (HRD) is involved in the development of high-grade serous ovarian carcinoma (HGSOC) and its elevated sensitivity to platinum-based chemotherapy. To investigate the heterogeneity of the HRD-positive HGSOC we evaluated the HRD status, including BRCA mutations, genomic scar score, and methylation status of BRCA1/2 genes in 352 HGSOC specimens. We then divided the HRD-positive cohort into three molecular subgroups, the BRCA mutation cohort (BRCA+), BRCA1 methylation cohort (Meth+), and the rest of the HRD+ cohort (HRD+BRCA-Meth-), and evaluated their first-line chemotherapy response, benefit from olaparib, and progression-free survival (PFS). HRD-positive status was detected in 65% (228/352) of samples. The first group, BRCA+, accounted for 45% (102/228) of HRD positive cases and showed the best outcome in platinum therapy (ORR 96%), the highest olaparib benefit (p = 0.006) and the highest median PFS (46 months). The frequency of the second cohort, Meth+, among HRD-positive patients was 23% (52/228). Patients with Meth+ HGSOC showed a significantly poorer outcome, with a median PFS of 19 months, a significantly lower ORR to platinum therapy (84%) and a modest, but not significant, benefit from olaparib maintenance. The third HRD+BRCA-Meth- group accounted for 32% (74/228) of HRD-positive patients and showed an ORR to platinum therapy similar to that of the BRCA+ group (90%), a higher, but not statistically significant, benefit from olaparib and a median PFS of 23 months. In conclusion, Meth+ subgroup had poor outcomes in terms of chemotherapy response, olaparib benefit, and PFS compared to the other HRD+ subgroups, requiring a more thorough follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBRCA2 ProteinDNA MethylationBRCA1 ProteinHumansFemaleMiddle AgedPrognosisAgedAdultMutationPhthalazinesRecombinational DNA RepairPiperazinesAged, 80 and overCystadenocarcinoma, Serous

Stichwörter der Autor:innen

BRCA1 methylationhomologous recombination deficiencyolaparib maintenanceprogression-free survival

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA1 protein, humanBRCA2 protein, humanolaparibPhthalazinesPiperazines

Autor:innen und Institutionen

  • Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.
  • Day Hospital No. 1, Moscow Municipal Oncological Hospital No. 62, 143515 Moscow, Russia.
  • Department of Pathology, Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia.
  • Department of Surgical Methods of Treatment No. 9, State Budgetary Healthcare Institution Regional Oncological Dispensary, 664035 Irkutsk, Russia.
  • Oncological Department of Medical Treatment, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after V. I. Kulakov, 117997 Moscow, Russia.
  • N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115522 Moscow, Russia.

ORCID-Profile: Tatiana Kekeeva, Alexander Tanas, Alexey Kalinkin, Natalia Chernorubashkina, Svetlana Khokhlova, Dmitry Zaletaev, Vladimir Strelnikov

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Kekeeva, T., Dudina, I., Andreeva, Y., Tanas, A., Kalinkin, A., Musatova, V., Chernorubashkina, N., Khokhlova, S., Tikhomirova, T., Volkonsky, M., Kutsev, S., Zaletaev, D., & Strelnikov, V. (2024). Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance. International Journal of Molecular Sciences, 25(24), 13549. https://doi.org/10.3390/ijms252413549

Vancouver

Kekeeva T, Dudina I, Andreeva Y, Tanas A, Kalinkin A, Musatova V, et al. Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance. International Journal of Molecular Sciences. 2024;25(24):13549. doi:10.3390/ijms252413549

BibTeX
@article{Kekeeva2024,
  author = {Kekeeva, Tatiana and Dudina, Irina and Andreeva, Yulia and Tanas, Alexander and Kalinkin, Alexey and Musatova, Victoria and Chernorubashkina, Natalia and Khokhlova, Svetlana and Tikhomirova, Tatiana and Volkonsky, Mikhail and Kutsev, Sergey and Zaletaev, Dmitry and Strelnikov, Vladimir},
  title = {Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {24},
  pages = {13549},
  doi = {10.3390/ijms252413549}
}
Kostenlos starten →